Atherosclerosis
Volume 199, Issue 2 , Pages 368-377 , August 2008

Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy

  • Laurent Laforest

      Affiliations

    • CHU Lyon, Unité de Pharmacoépidémiologie, Service Neurologie, Hopital Pierre, Wertheimer, Bron F-69677, France
    • ,
  • Philippe Moulin

      Affiliations

    • Endocrinology, CHU-Lyon, France
    • ,
  • Thierry Souchet

      Affiliations

    • Merck Sharp & Dohme, Chibret, Paris, France
    • ,
  • Cécile Ritleng

      Affiliations

    • CHU Lyon, Unité de Pharmacoépidémiologie, Service Neurologie, Hopital Pierre, Wertheimer, Bron F-69677, France
    • ,
  • Gaëlle Desamericq

      Affiliations

    • CHU Lyon, Unité de Pharmacoépidémiologie, Service Neurologie, Hopital Pierre, Wertheimer, Bron F-69677, France
    • ,
  • Philippe Le Jeunne

      Affiliations

    • Cegedim Strategic Data, Boulogne, France
    • ,
  • Marie-Sophie Schwalm

      Affiliations

    • Cegedim Strategic Data, Boulogne, France
    • ,
  • Alexia Kieffer

      Affiliations

    • Pierre and Marie Curie University, Paris 6, UMR S 707, Paris, France
    • ,
  • Eric Van Ganse

      Affiliations

    • CHU Lyon, Unité de Pharmacoépidémiologie, Service Neurologie, Hopital Pierre, Wertheimer, Bron F-69677, France
    • Corresponding Author InformationCorresponding author at: Unité de Neuro-épidémiologie et de Pharmaco-épidémiologie, Hopital Neurologique Pierre Wertheimer, 59, Boulevard Pinel, 69677 Bron Cedex, France. Tel.: +33 472 129; 709; fax: +33 472 129 714.

Received 16 August 2007 ,Revised 31 October 2007 ,Accepted 15 November 2007.

References 

  1. 4S Primary Paper Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet. 1994;334:1383–1389
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  3. Heart Protection Study primary paper Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20536 high-risk individuals: a randomized placebo-controlled group. Lancet. 2002;360:7–22
  4. Baigent C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  5. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol. 2005;59:456–463
  6. Therapeutic management of dyslipidemic patients: guidelines. Saint Denis, France: French Health Products Safety Agency (AFSSAPS); updated on 2005. http://www.afssaps.sante.fr.
  7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  8. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  9. Garcia Ruiz FJ, Marin Ibanez A, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The reality study. Pharmacoeconomics. 2004;22(Suppl. 3):1–12
  10. Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs. 2006;6:121–128
  11. Yan AT, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676–683
  12. Walley T, et al. Variations and increase in use of statins across Europe: data from administrative databases. BMJ. 2004;328:385–386
  13. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study—Observational (CALIPSO). Can J Cardiol. 2005;21:1187–1193
  14. Hoskins MH, Jacobson TA. Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. J Natl Med Assoc. 2006;98:58–62
  15. Alsheikh-Ali AA, et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol. 2006;98:1231–1233
  16. O’Connor PJ, Gray RJ, Maciosek MV, et al. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. Prev Chronic Dis. 2005;2:A05
  17. Deambrosis P, Saramin C, Terrazzani G, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003. Eur J Clin Pharmacol. 2007;63:197–203
  18. Diamantopoulos EJ, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology. 2005;56:731–741
  19. Stein EA. The power of statins: aggressive lipid lowering. Clin Cardiol. 2003;26:III25–III31
  20. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001;111:185–191
  21. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manage Care. 2006;12:S405–S411
  22. Parris ES, Lawrence DB, Mohn LA. Long LB adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28:595–599
  23. Banta MR, Ma F, Bravata DM, Kirsner RS, Federman DG. Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease. J Gen Intern Med. 2006;21:711–714
  24. Schultz JS, O’Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manage Care. 2005;11:306–312
  25. Ye X, Gross CR, Schommer J, et al. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm. 2007;13:385–396
  26. Van Ganse E, Souchet T, Laforest L, et al. Lipid levels in high risk dyslipidemic patients treated in primary cardiovascular prevention and effect on outcomes: an observational study. Atherosclerosis. 2006;185:58–64
  27. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667–674
  28. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6:148–157

PII: S0021-9150(07)00741-1

doi: 10.1016/j.atherosclerosis.2007.11.033

Atherosclerosis
Volume 199, Issue 2 , Pages 368-377 , August 2008

Article Tools

* Image Usage & Resolution